Cargando…
Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398095/ https://www.ncbi.nlm.nih.gov/pubmed/32818152 http://dx.doi.org/10.1136/bmjophth-2020-000538 |
_version_ | 1783565895705034752 |
---|---|
author | Terao, Etsuko Nakakura, Shunsuke Fujisawa, Yasuko Nagata, Yuki Ueda, Kanae Kobayashi, Yui Oogi, Satomi Dote, Saki Shiraishi, Miku Tabuchi, Hitoshi Yoneda, Tsuyoshi Fukushima, Atsuki Asaoka, Ryo Kiuchi, Yoshiaki |
author_facet | Terao, Etsuko Nakakura, Shunsuke Fujisawa, Yasuko Nagata, Yuki Ueda, Kanae Kobayashi, Yui Oogi, Satomi Dote, Saki Shiraishi, Miku Tabuchi, Hitoshi Yoneda, Tsuyoshi Fukushima, Atsuki Asaoka, Ryo Kiuchi, Yoshiaki |
author_sort | Terao, Etsuko |
collection | PubMed |
description | OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software. RESULTS: In omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction). CONCLUSION: Conjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly. |
format | Online Article Text |
id | pubmed-7398095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73980952020-08-17 Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% Terao, Etsuko Nakakura, Shunsuke Fujisawa, Yasuko Nagata, Yuki Ueda, Kanae Kobayashi, Yui Oogi, Satomi Dote, Saki Shiraishi, Miku Tabuchi, Hitoshi Yoneda, Tsuyoshi Fukushima, Atsuki Asaoka, Ryo Kiuchi, Yoshiaki BMJ Open Ophthalmol Original Research OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software. RESULTS: In omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction). CONCLUSION: Conjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly. BMJ Publishing Group 2020-08-02 /pmc/articles/PMC7398095/ /pubmed/32818152 http://dx.doi.org/10.1136/bmjophth-2020-000538 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Terao, Etsuko Nakakura, Shunsuke Fujisawa, Yasuko Nagata, Yuki Ueda, Kanae Kobayashi, Yui Oogi, Satomi Dote, Saki Shiraishi, Miku Tabuchi, Hitoshi Yoneda, Tsuyoshi Fukushima, Atsuki Asaoka, Ryo Kiuchi, Yoshiaki Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title | Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title_full | Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title_fullStr | Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title_full_unstemmed | Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title_short | Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
title_sort | time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398095/ https://www.ncbi.nlm.nih.gov/pubmed/32818152 http://dx.doi.org/10.1136/bmjophth-2020-000538 |
work_keys_str_mv | AT teraoetsuko timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT nakakurashunsuke timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT fujisawayasuko timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT nagatayuki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT uedakanae timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT kobayashiyui timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT oogisatomi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT dotesaki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT shiraishimiku timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT tabuchihitoshi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT yonedatsuyoshi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT fukushimaatsuki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT asaokaryo timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 AT kiuchiyoshiaki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04 |